Altman Z″
Needs current assets and current liabilities.
PRAMODINI · Hospital & Healthcare Services · INE2JG601017
Analyst mean 0.00 · 0 analysts · 0% bullishThis company listed within the last twelve months, so its prospectus is still the primary source. The figures below were extracted from the DRHP and RHP before listing and scored then, and they are shown here as they stand in the IPO record rather than restated.
Each flag is a fact read in the filing, shown with the context that makes it meaningful.
Stated objects, as worded in the offer document. Deployment against them is tracked separately.
Claims made in the offer document, to be read against what the company has reported since.
Pramodini Medicare Limited provides a comprehensive range of technology-enabled diagnostic services, including MRI, CT scans, ultrasound, and PET-CT oncology imaging. Originally incorporated on September 12, 2000, as 'Pramodini Medicare Private Limited' in Vijayawada, Andhra Pradesh, the company operates its diagnostic centers primarily from leased premises. Its expansion plans involve setting up proposed diagnostic centers and upgrading existing facilities in locations such as Vijayawada, Bangalore, Hubli, and Manjari. The company has placed medical equipment orders with suppliers like Truevis Technologies Private Limited, but has not yet finalized orders for all proposed diagnostic devices. Its customer base consists of individual patients and healthcare providers utilizing diagnostic services. The company delivers its diagnostic and imaging services directly to patients through its diagnostic centers.
Strategic presence across various states of India, a strong network with diversified models, technical capability with robust IT infrastructure, and a diverse customer and patient base.
Short: Pramodini Medicare Limited is an Indian diagnostic service provider offering technology-enabled diagnostic and imaging services.
Source: p. 106
The comparable set the company chose, which is itself a disclosure.
| Name | Margin | Pb | Pe | Roe | Source |
|---|---|---|---|---|---|
| Pramodini Medicare Limited | 32.69 | p. 107 | |||
| Invicta Diagnostic Limited | 13.62 | 9.76 | p. 108 | ||
| Krsnaa Diagnostics Limited | 16.74 | 10.35 | p. 108 | ||
| Star Imaging & Path Labs Limited | 7.87 | 16.58 | p. 108 |
As presented in the offer document. Post-listing figures are in the statements above.
| Basis | Period | Related party revenue cr | Pat cr | Ebitda cr | Pat margin | Revenue cr | Pat margin derived |
|---|---|---|---|---|---|---|---|
| consolidated | FY26 | 0.9271 | 17.3773 | 30.9035 | 27.9% | 62.2875 | yes |
| consolidated | FY25 | 0.0805 | 11.0276 | 20.9661 | 28.84% | 38.2377 | yes |
| consolidated | FY24 | 0.3016 | 6.9301 | 15.5347 | 19.67% | 35.2295 | yes |
Written before listing, answered from the document itself.
How are the fresh issue proceeds being deployed?
Proceeds are earmarked for funding capital expenditure for the purchase of medical equipment for existing and proposed diagnostic centers (Rs 45.15 Cr). The balance is allocated to general corporate purposes and unidentified inorganic acquisitions, subject to a combined cap of 35% of Gross Proceeds (with unidentified acquisitions limited to
p. 31, 97, 98
Who are the promoters and what is their acquisition cost?
The promoters are Dr. Chalasani Kuldeep Kumar, Dr. Chalasani Kavitha, Ms. Chalasani Durga Aashritha, and M/s. Sri Ram Medicare Private Limited, holding 85.71% pre-issue. Due to a 12:1 bonus issue in March 2026, the weighted average cost of acquisition for secondary transactions stands at Rs 34.95 per equity share.
p. 82, 84, 92, 111, 112, 180
Are there material related-party transactions or balance-sheet exposures?
Yes. The company has given loans to associate Vista Pramodini Medicare Pvt Ltd (outstanding receivable of Rs 7.34 Cr in FY26) and paid Rs 0.61 Cr in manpower charges to Infer Radiological & Imaging Services Pvt Ltd. It has also extended an outstanding corporate guarantee of Rs 4.95 Cr on behalf of promoter group entity Sri Ram Medicare Pvt Ltd.
p. F-2, 333, 334
Does operating cash flow align with reported profits?
Yes, exceptionally well. Operating cash flow (CFO) has consistently exceeded reported PAT over the last three years: FY26 CFO was Rs 25.39 Cr vs PAT of Rs 17.38 Cr; FY25 CFO was Rs 22.12 Cr vs PAT of Rs 11.03 Cr; and FY24 CFO was Rs 9.85 Cr vs PAT of Rs 6.93 Cr. This indicates high earnings quality.
p. 26, 65, 66, 67, 161, 162
What structural market parameters apply to this offer?
The offer consists of a Fresh Issue of up to 53,50,800 shares and an OFS of up to 5,00,400 shares. Shreni Shares Limited and Rainbow Securities Private Limited act as joint market makers (up to 3,36,000 shares reserved). Post-issue capital is structured at Rs 22.05 Cr (2,20,45,595 shares of face value Rs 10 each), allowing listing on the NSE Emerge platform.
p. 1, 8, 9, 61, 71, 79, 327
What the issue priced at, on the figures in the document.
| Date | Name | Shares | Price per share | Category | Issue type | Source |
|---|---|---|---|---|---|---|
| 2000-09-12 | Initial Subscribers (Mr. Raja Rao Yalamanchili and Ms. Hymavathi Yalamanchali) | 20 | 10 | promoter group | initial | p. 83, 84 |
| 2004-03-31 | Further Allotment | 94990 | 10 | other | preferential | p. 83 |
| 2011-03-25 | Further Allotment | 900000 | 10 | other | preferential | p. 83 |
| 2018-03-21 | Ms. Hymavathi Yalamanchali to Dr. Chalasani Kuldeep Kumar | 135000 | 80.93 | promoter | transfer | p. 89 |
| 2018-03-21 | Mr. Raja Rao Yalamanchili to Dr. Chalasani Kuldeep Kumar | 80010 | 80.93 | promoter | transfer | p. 89 |
| 2018-04-02 | Ms. Hymavathi Yalamanchali to Dr. Chalasani Kavitha | 30000 | 80.93 | promoter | transfer | p. 90 |
| 2018-04-02 | Mr. Raja Rao Yalamanchili to Dr. Chalasani Kavitha | 95749 | 80.93 | promoter | transfer | p. 90 |
| 2020-02-12 | Share Sub-division / Split (face value ₹10 to ₹1) | other | split | p. 90 | ||
| 2025-03-10 | Dr. Chalasani Kuldeep Kumar to Mr. Yash Hitesh Patel | 642120 | 31 | other | transfer | p. 91, 111 |
| 2025-03-17 | Dr. Chalasani Kuldeep Kumar to Ms. Sumita Mishra | 256840 | 31 | other | transfer | p. 91, 111 |
| 2025-03-30 | Share Consolidation (face value ₹1 to ₹10) | other | split | p. 84, 91 | ||
| 2025-04-02 | Dr. Chalasani Kuldeep Kumar to Mr. Siva Rama Krishna Prasad Atluri | 6451 | 310 | other | transfer | p. 91, 111 |
| 2025-04-02 | Dr. Chalasani Kuldeep Kumar to Ms. Karri Mani Kumari | 3225 | 310 | other | transfer | p. 111 |
| 2025-04-03 | Dr. Chalasani Kuldeep Kumar to Mr. Swapnil Sudhakarrao Topale | 3225 | 310 | other | transfer | p. 111 |
Ceo: Dr. Chalasani Kuldeep Kumar
TDS demands against the Company: 7 cases u/s Rs 0.0039 Cr. Direct Tax demands against Promoters: 12 cases u/s Rs 0.0151 Cr. Direct Tax demands against Group Companies: 10 cases u/s Rs 0.1008 Cr. Pending Civil Suit u/s Independent Director (Ajay Kumar Attaluri): 1 case (amount unascertainable). Ongoing civil/writ petition against Group Company (Infer Radiological): 1 case (amount unascertainable).
Auditor name: M/s. S S S S & Associates, Chartered Accountants
Skin in game: 85.71%
Auditor report (Note A u/s secured loans) discloses that underlying sanction letters/loan agreements for certain borrowings were not readily available at the reporting date. Further, Note 17 u/s additional notes indicates that the Company availed borrowings u/s security of current assets but did not submit monthly returns/statements of current assets to banks, preventing reconciliation of material discrepancies.
Auditor changed last 3y: Yes
Source: p. 3, 5, 29, 82, 92, 95, 121, 124, 147, 186, 235, 291, 329, 393
Numbered markers are corporate actions and, once the filings are read, capital and governance events. Prices are split-adjusted so the series is continuous.
What the numbers mean when read together — computed from the filings, not a score.
Free cash flow is negative — the business consumes more than it generates once capex is paid. Fine if it is deliberate growth investment; a problem if it is structural.
Why this reading: Noted with caution — worth watching, but not yet conclusive on its own. Business has ups and downs; one soft reading is not a verdict.
Latest free cash flow ₹-4 cr, negative in 1 of 3 years. Check whether the burn funds expansion (dark stores, plants, ports) or merely sustains operations.
Operating cash is 147% of trailing profit — the earnings are converting to real cash, not just accruals.
Why this reading: A positive signal: cash conversion at or above ~0.9 means reported profit is showing up as actual cash.
Operating cash ₹25 cr against trailing net profit ₹17 cr. Consistent conversion near or above 1.0 is a hallmark of genuine earnings.
Debt rose over 2 years, and most of it (467%) has turned into fixed assets and projects under construction — the borrowing is building the business.
Why this reading: A positive signal: leverage taken on is visibly becoming productive capacity, not disappearing.
New borrowing ₹6 cr largely matched by an asset build of ₹28 cr. Debt that funds capacity is a different thing from debt that funds nothing.
Every score below is calculated here from the reported numbers — none of it is asserted. Open the notebook at the foot of the section to see each formula with this company's figures in it.
Needs current assets and current liabilities.
Piotroski F-Score — fundamental momentum — Joseph Piotroski, University of Chicago, 2000, in a study of whether accounting signals could improve returns among cheap stocks.
Nine yes-or-no tests across profitability, leverage and operating efficiency. Each pass scores one. It asks a narrow question: is this business getting better or worse on its own terms, year over year?
How to read it7 or more suggests improving fundamentals; 3 or fewer suggests deterioration. It measures direction, not quality — a weak company improving can score higher than a strong one holding steady.
Where it failsA single year of comparison, so one unusual year distorts it. Says nothing about valuation, competitive position or management. Piotroski designed it to rank already-cheap stocks, not to judge a company in isolation.
Needs trade receivables, current assets, other expenses.
Accruals are -10.7% of assets. Free cash flow negative in 1 of 3 years.
DuPont decomposition — Devised inside the DuPont Corporation in the 1920s and still the standard way to read a return on equity.
Splits return on equity into its three sources, so the same headline number can be traced to very different businesses.
How to read itA 20% ROE built on margin and turnover is a different proposition from a 20% ROE built on 3× leverage. The first survives a downturn; the second amplifies it.
Where it failsA single year. Negative equity makes it meaningless. Leverage is structural for lenders, so the third term carries no signal there.
Capital is going in far faster than revenue is coming out. For a business mid-build that is expected — the test is whether it converts.
cumulative operating cash flow ÷ cumulative net profit
₹57 cr ÷ ₹35 cr, over 3 years
1.63×
Above 1.0 means cash exceeds reported profit — the healthier reading.(net profit − operating cash flow) ÷ average total assets
(₹17 − ₹25) cr ÷ average assets
-10.7%
Negative means cash exceeded profit — the healthier reading. Positive above ~10% is where accruals start to dominate earnings.net margin × asset turnover × leverage
27.4% × 0.66 × 1.77
32.1%
Splits ROE into whether returns come from operations or from borrowing.EBIT ÷ finance cost
₹24 cr ÷ ₹1 cr
24.00×
How many times operating profit covers the interest bill.borrowings ÷ net worth
₹18 cr ÷ ₹53 cr
0.34×
Read against the sector — infrastructure carries more than software.growth in fixed assets + CWIP, against growth in revenue
capital +175% vs revenue +77%, FY2024 to FY2026
98pp gap
Money going in far faster than revenue coming out. For an incubator this is expected — the test is whether it eventually converts.Needs more balance-sheet detail (only 3 of 6 flags testable).
NOPAT over equity plus debt less cash, at a notional 25% tax. Incremental ROIC is the return on money put in since then — the number that decides whether growth creates value or consumes it.
Return on invested capital, and incremental ROIC — Standard in corporate finance; the incremental form was popularised by Michael Mauboussin as the test of whether growth creates value.
ROIC measures what the business earns on all the capital it employs — equity plus debt, less cash. Incremental ROIC asks a sharper question: what has it earned on the money put in since a chosen year?
How to read itROIC comfortably above the cost of capital — call it 11–13% in India — means growth compounds. Below it, growth consumes. Incremental below headline means recent investment is earning less than the legacy business.
Where it failsDistorted in the year of a large acquisition. Understated for companies mid-build, where capital is deployed but capacity has not yet been commissioned — an incubator will look poor until it does not.
Read downward. Cash can cover EBITDA and still not survive capex — the third rung is where a capital-hungry business shows itself.
The earnings quality ladder — Not a named model — the standard sequence an analyst walks when testing whether reported profit is real.
Three ratios read in order, each stricter than the last.
How to read itRead downward. Each rung failing where the one above passed tells you exactly where the cash is going.
Where it failsA single year of heavy capex depresses the third rung legitimately. Judge it across a cycle.
Against a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%.
Cost of debt — Interest expense over average borrowings — the effective rate the company actually pays.
What the lenders charge, which is a market verdict on credit quality that no rating agency delay affects.
How to read itAgainst a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%. Read the direction over years as much as the level.
Where it failsUnderstated where a large share of interest is capitalised into projects under construction. Not meaningful for lenders, where interest is cost of goods.
Models that need these lines are withheld rather than estimated: net worth, current assets, current liabilities, trade receivables, inventory, net block. Nothing on this page is back-solved from a figure the company did not publish.
Each framework below is a set of stated, mechanical criteria from published work, run against this company's own filed numbers. Passing or failing a screen is not a verdict — different frameworks disagree by design, and that disagreement is itself informative.
Benjamin Graham's stated criteria for a defensive stock, applied to the filed numbers. A company failing several is not disqualified — Graham designed these to be deliberately strict.
Two ratios only: what the business earns on its capital, and what you pay for those earnings. Designed to be ranked across a universe rather than read in isolation.
The fundamental half of William O'Neil's framework. The market and leadership components are judgement calls and are not scored here.
The characteristics long-term holders commonly look for: cash-backed earnings, high returns on capital, and debt that never forces a decision.
Bars are revenue; the line is net margin. Revenue rising while the line falls is the shape worth noticing.
Operating cash first, then what the business spent and raised.
One year is a snapshot. These are the two lines that matter across a cycle.
Rising debtor or inventory days against flat sales is the earliest visible sign of stress.
Set your own assumptions and watch the numbers move. A scenario calculator — the outputs are the arithmetic of your inputs.
One canonical set of figures — the same numbers used everywhere else on this page and on the screener.
Where cash gets stuck. A rising inventory or debtor line against flat sales is the earliest sign of trouble in the numbers.
| Measure | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Debtor days
How long customers take to pay | 186 | 107 | 102 |
| Cash conversion cycle
Debtor + inventory − payable days | 186 | 107 | 102 |
| Working capital days | 16 | 0 | 2 |
| ROCE %
Return on capital employed | — | 41.0% | 42.0% |
The shape of the business over time (annual) — read the direction, not the single print.
| Line | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue from operations | 35 | 38 | 62 |
| Other income | 1 | 0 | 1 |
| Depreciation | 4 | 4 | 7 |
| Finance cost | 2 | 1 | 1 |
| Profit before tax | 10 | 16 | 23 |
| Net profit (owners) | 7 | 11 | 17 |
| EPS (₹) | 5.40 | 85.89 | 10.41 |
Exceptional items, total income and EBITDA are read from the filed statements.
| Item | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Equity Capital | 1 | 1 | 17 |
| Reserves | 23 | 34 | 36 |
| Borrowings | 12 | 11 | 18 |
| Net block | 16 | 22 | 44 |
| CWIP | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| Total Assets | 49 | 56 | 94 |
| Line | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Cash from operations | 10 | 22 | 25 |
| Cash from investing | -1 | -15 | -31 |
| Cash from financing | -11 | -2 | 6 |
| Free cash flow | 9 | 12 | -4 |
| Net change in cash | -2 | 5 | 0 |
Cash from operations is the number profit has to answer to. Free cash flow is what remains after the business pays for its own growth.
These are coverage counts, not ratings. Each one asks a fixed set of questions of the filings and reports how many the company answered. A company that discloses nothing counts nothing here — that is a statement about the disclosure, not about the business.
The same read, applied to the companies this one competes with.